2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-101668
    Sulamserod 219757-90-1 98%
    Sulamserod is a 5-HT4 receptor antagonist, with antiarrhythmic activities.
    Sulamserod
  • HY-101674
    Tiapamil hydrochloride 57010-32-9 98%
    Tiapamil hydrochloride is a calcium channel blocker.
    Tiapamil hydrochloride
  • HY-101681
    Utibapril 109683-61-6 98%
    Utibapril is an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activities.
    Utibapril
  • HY-101685
    Iganidipine 119687-33-1 98%
    Iganidipine is a Ca2+ antagonist.
    Iganidipine
  • HY-101691
    Ecastolol 77695-52-4 98%
    Ecastolol is a beta adrenergic receptor antagonist, with antianginal activities.
    Ecastolol
  • HY-101700
    LCB-2853 141335-10-6 98%
    LCB-2853 is an antagonist of thromboxane A2 (TXA2) receptor, with antiplatelet and antithrombotic activities.
    LCB-2853
  • HY-101706
    CGP48369 135689-23-5 98%
    CGP48369 is a nonpeptidic angiotensin II receptor antagonist, used for anti-hypertensive research.
    CGP48369
  • HY-101720
    Fradafiban 148396-36-5 98%
    Fradafiban is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM.
    Fradafiban
  • HY-101721
    Ko-3290 79848-61-6 98%
    Ko-3290 is an antagonist of β-adrenoceptor, with cardioselectivity and antilipolytic effects in animals. Ko-3290 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Ko-3290
  • HY-101727
    Nexopamil racemate 116759-35-4 98%
    Nexopamil racemate is the racemate of Nexopamil. Nexopamil is a combined Ca2+/5-HT2 antagonist on thrombus formation in vivo and on platelet aggregation in vitro.
    Nexopamil racemate
  • HY-101733
    Zabicipril hydrochloride 90130-77-1 98%
    Zabicipril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor. Zabicipril hydrochloride can be used for the study of blood pressure and peripheral arterial insufficiency.
    Zabicipril hydrochloride
  • HY-101775
    9-Hydroxyellipticin 51131-85-2 98%
    9-hydroxyellipticine is an inhibitor of Topo II and RyR, exhibiting high affinity for DNA with a Pka value of 9.8 at pH 7.4. It has antitumor, antioxidant, and catecholamine-releasing activities, with IC50 values of 1.6 μM and 1.2 μM for Hela S-3 and 293T cells, respectively. It also demonstrates anticancer effects in L1210 leukemia mice.
    9-Hydroxyellipticin
  • HY-101804
    (E)-Alprenoxime 125720-84-5 98%
    (E)-Alprenoxime is the isomer of the Alprenoxime. Alprenoxime is a site-activated ocular β-blocker.
    (E)-Alprenoxime
  • HY-101807
    Ro-15-2041 77448-87-4 98%
    Ro 15-2041 is a selective platelet phosphodiesterase inhibitor with antithrombotic properties.
    Ro-15-2041
  • HY-101809
    CNS-5161 hydrochloride 160756-38-7 98%
    CNS-5161 hydrochloride is a novel NMDA ion-channel antagonist that interacts with the NMDA receptor/ion channel site to produce a noncompetitive blockade of the actions of glutamate.
    CNS-5161 hydrochloride
  • HY-101811
    LAS-31180 137338-43-3 98%
    LAS-31180 is an inhibitor of phosphodiesterase 3, with positive inotropic and vasodilator properties.
    LAS-31180
  • HY-102092
    FR139317 142375-60-8 98%
    FR139317 (PD 147953) is a selective ETA receptor antagonist. FR139317 inhibits cerebral activation by intraventricular endothelin-1 in conscious rats. FR139317 also ameliorates cerebral vasospasm in dogs.
    FR139317
  • HY-10264D
    (1R,2R,4R)-Edoxaban 1255529-24-8 98%
    (1R,2R,4R)-Edoxaban is an oxalamide derivative. (1R,2R,4R)-Edoxaban is an activated coagulation factor X (Factor Xa) inhibitor. (1R,2R,4R)-Edoxaban can be used in the study of thrombosis.
    (1R,2R,4R)-Edoxaban
  • HY-10264R
    Edoxaban (Standard) 480449-70-5
    Edoxaban (Standard) is the analytical standard of Edoxaban. This product is intended for research and analytical applications. Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research.
    Edoxaban (Standard)
  • HY-10268R
    Betrixaban (Standard) 330942-05-7 98%
    Betrixaban (Standard) is the analytical standard of Betrixaban. This product is intended for research and analytical applications. Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban shows antithrombotic effect.
    Betrixaban (Standard)
Cat. No. Product Name / Synonyms Application Reactivity